{"title":"Methylphenidate (Ritalin) does not improve exam performance in an experimental setting.","authors":"Anke Sambeth, Monika Toth, Arjan Blokland","doi":"10.1007/s00213-025-06864-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Surveys indicate that about 10-20% of students use medicinal drugs to improve their exam performance. Whether these drugs really improve exam performance has not been examined in an experimental setting yet. This study tested the effects of methylphenidate (MPH; 20 mg) on exam performance either by giving the drug before studying for an exam (day 1, acquiring new information) or before the exam was taken (day 2, retrieving the information).</p><p><strong>Method: </strong>For this study, a double-blind placebo controlled between-subjects design was applied. The participants were randomly assigned to three groups that were given treatment on the two days: Placebo-Placebo (n = 25), MPH (n = 24), Placebo-MPH (n = 26). The exam contained multiple-choice questions (factual knowledge and inference questions) and open questions (inference).</p><p><strong>Results: </strong>The data showed that MPH did not improve the exam performance on the three types of questions. In addition, the average grade did not differ between the three groups and the number of participants failing or passing the exam did not differ.</p><p><strong>Conclusion: </strong>This is a first experimental study showing that MPH does not improve exam performance and should discourage students to take MPH during exam periods.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06864-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale: Surveys indicate that about 10-20% of students use medicinal drugs to improve their exam performance. Whether these drugs really improve exam performance has not been examined in an experimental setting yet. This study tested the effects of methylphenidate (MPH; 20 mg) on exam performance either by giving the drug before studying for an exam (day 1, acquiring new information) or before the exam was taken (day 2, retrieving the information).
Method: For this study, a double-blind placebo controlled between-subjects design was applied. The participants were randomly assigned to three groups that were given treatment on the two days: Placebo-Placebo (n = 25), MPH (n = 24), Placebo-MPH (n = 26). The exam contained multiple-choice questions (factual knowledge and inference questions) and open questions (inference).
Results: The data showed that MPH did not improve the exam performance on the three types of questions. In addition, the average grade did not differ between the three groups and the number of participants failing or passing the exam did not differ.
Conclusion: This is a first experimental study showing that MPH does not improve exam performance and should discourage students to take MPH during exam periods.
期刊介绍：
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
